The headlines from Canada scream scarcity: Ozempic, the diabetes drug turned Hollywood’s secret weapon for weight loss, is running out. Patients who rely on it for blood sugar control are scrambling, while across the border, America’s pharmaceutical free-for-all is being blamed for hoarding supply. But in Britain, a quieter story is unfolding. The NHS’s collective bargaining and strict prescribing guidelines mean that, for now, the drug remains accessible to those who truly need it. The contrast is a study in social values.
Ozempic has become a cultural phenomenon: a once-a-week injection that promises svelte bodies, celebrities whispering its name, and a booming black market. But in Canada, the demand has outpaced supply, leaving diabetic patients rationing doses. The US, with its profit-driven system, has been accused of cornering the global market. Around 10 million Americans now use GLP-1 agonists like Ozempic, many for cosmetic weight loss. The result? A drug shortage that the World Health Organization might call a crisis, but the FDA calls an inconvenience.
Yet the real story is not just about stocks of semaglutide. It is about how healthcare systems reflect national character. In Canada, a publicly funded system struggles to compete with American wealth. Patients report being denied refills, told to try older drugs. The human cost is palpable: a teacher in Toronto told me she spends hours on the phone, begging pharmacies for her husband’s prescription. “It’s like we’re second-class citizens,” she said. “The US gets to buy up everything because they pay more.”
Enter Britain’s NHS. The model is unfashionably socialist: centralised purchasing, tough negotiations with drug companies, and clinical guidelines that prioritise medical need over desire. While the US debates a patient’s right to buy Ozempic online without a prescription, Britain has already said no. The National Institute for Health and Care Excellence (NICE) restricts the drug to those with Type 2 diabetes and a body mass index over 35. Weight loss without a prescription is private only, and costly.
The cultural shift is subtle but seismic. In London, a pharmacist told me that queries for Ozempic have risen 400%, but few are approved. “Patients are angry,” he said. “They see it on Instagram and think it’s a miracle. But we have to ration, ethically.” The system isn’t perfect: supply shortages have hit the UK too, but they are managed. The NHS can switch patients to alternatives or adjust doses. There is no panic because there is no free market.
This is not a simple tale of triumph. Britain’s model has critics: it can be slow to approve new drugs and can feel paternalistic. But the Canadian crisis exposes a deeper truth. Pharmaceutical companies will always prioritise the highest bidder. In a world where obesity is a private struggle and a public health burden, who decides who gets the cure? America says the market; Canada says the state but can’t enforce it; Britain says the doctor.
Walking through a London clinic, I saw a poster: “Ozempic: not for vanity.” It seemed harsh. But then I thought of the Canadian teacher, the US influencer with a fridge full of vials, and the NHS diabetic who just got their prescription refilled. The human element is not just about access; it is about fairness. The drug does not discriminate, but our systems do. Britain’s approach is not perfect, but in a crisis, it holds a mirror to what we value: collective health over individual desire.
As the Canadian story develops, the world watches. Could this shortage force America to rethink its pharmaceutical model? Unlikely. But for now, the NHS offers a calm in the storm, a reminder that public health is not a commodity. And that, perhaps, is the most radical idea of all.
